Similarly, CD160 expression was observed to be higher in CLL patients, as well as Ps patients, compared to HVs (86.94 vs. 11.96, p < 0.0001), (48.92 vs. 11.96 p < 0.0001), respectively, and CD160 expression was higher in CLL patients compared to Ps patients (86.94 vs. 48.92, p = 0.0243) (Figure 1b). The gene discussed is CD160; the disease is B-cell chronic lymphocytic leukemia.